Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Cardiotronics

This article was originally published in The Gray Sheet

Executive Summary

Has reached a tentative agreement to buy the 1 mil. shares of R2 Medical Systems held by the Ventana Growth Fund, L.P. and the Ventana Growth Fund II, L.P. for a price of $6.50 per share as part of its effort to buy the firm. Cardiotronics had previously announced an agreement, pending due diligence, to purchase the shares from Darox Corp. ("The Gray Sheet" July 4, p. 33). Darox is R2's former parent and is owned by the Ventana entities. Cardiotronics is also is attempting to purchase the remaining 1.65 mil. shares of R2 common stock for $5.25 per share. R2 says the offer is still in the negotiating stage and no formal agreements have been reached. R2 rejected Cardiotronics previous offer to purchase the company at $4 a share in May ("The Gray Sheet" May 16, p. 24)

You may also be interested in...



Will MDR Delays Create Roadblocks For Companion Diagnostics Regulation?

Companion diagnostics are needed increasingly by pharma companies to justify the safety and effectiveness of their products. With specific first-time EU regulation of these products within sight – and urgently needed is there a risk of delays to these products being able to demonstrate compliance?

India Rare Disease Policy Proposes Crowdfunding But Patients Feel Let Down

Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.

India’s Hilleman Plans ‘Affordable’ Vaccine Against Group B Strep

India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.

UsernamePublicRestriction

Register

MT002619

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel